Breaking News Instant updates and real-time market news.

BMY

Bristol-Myers

$58.65

-0.19 (-0.32%)

16:38
04/13/18
04/13
16:38
04/13/18
16:38

Bristol-Myers reports 'positive' results from Phase 3 CheckMate -078 trial

Bristol-Myers announced results from the pivotal, randomized Phase 3 CheckMate -078 trial evaluating Opdivo versus docetaxel in a predominantly Chinese population with previously treated advanced non-small cell lung cancer. In the study, Opdivo demonstrated a statistically significant benefit versus docetaxel on the primary endpoint of overall survival. An OS benefit was observed regardless of PD-L1 expression or tumor histology. Additionally, the two secondary endpoints of objective response rate and median duration of response demonstrated durability with Opdivo compared with docetaxel. In CheckMate -078, Grade 3-4 treatment-related adverse events occurred less frequently with Opdivo versus docetaxel (10% vs 47%). Discontinuation due to Grade 3-4 TRAEs were less frequent with Opdivo (3%) than with docetaxel (5%). Findings will be presented on Monday, April 16 from 4:05-4:20 PM CDT during the Updates in Immuno-Oncology Trials session at the American Association for Cancer Research Annual Meeting 2018 in Chicago.

  • 14

    Apr

  • 26

    Apr

  • 08

    May

  • 21

    May

  • 10

    Jul

BMY Bristol-Myers
$58.65

-0.19 (-0.32%)

04/12/18
SBSH
04/12/18
NO CHANGE
Target $70
SBSH
Buy
Bristol-Myers price target lowered to $70 from $78 at Citi
Citi analyst Andrew Baum lowered his price target for Bristol-Myers Squibb (BMY) to $70 after Pfizer (PFE) management made clear to him that they had no interest in acquiring Bristol without transformational data or a de-rating in the shares. The analyst removed the $8 per share risk adjusted M&A premium from his Bristol-Myers target price. He views his new price target as conservative, however, and keeps a Buy rating on the name.
04/12/18
SBSH
04/12/18
NO CHANGE
SBSH
Sell
Pfizer has no interest in acquiring Bristol-Myers right now, says Citi
Citi analyst Andrew Baum says Pfizer's (PFE) CEO made it clear to him that the company has no interest in acquiring Bristol-Myers Squibb (BMY) in the absence of transformational data or a de-rating in the shares. Pfizer has high conviction in its current pipeline and believes that the return on investment is considerably higher than high risk transformational deals, particularly in the immuno-oncology space, Baum tells investors in a research note. The analyst expects Pfizer will meaningfully increase its current share repurchase program from the current $5B-$6B per annum to offset the earnings dilution from higher anticipated R&D investment to monetize its current pipeline. Baum keeps a Sell rating on Pfizer and continues to prefer shares of Merck (MRK), Bristol and Eli Lilly (LLY) in the U.S. The analyst lowered his price target for Bristol shares to $70 from $78 with Pfizer backing away from a potential takeover. He keeps a Buy rating on the shares, however.
04/09/18
HCWC
04/09/18
NO CHANGE
Target $125
HCWC
Buy
Nektar data 'more robust' than Incyte's, says H.C. Wainwright
The failure of Incyte (INCY) and Merck's (MRK) Phase 3 study negatively impacted trading in Nektar Therapeutics (NKTR) shares on Friday, H.C. Wainwright analyst Debjit Chattopadhyay tells investors in a research note titled "Collateral Damage Not Surprising; Expecting ASCO-18 to Validate the Master T Cell Regulator Hypothesis." At this year's American Society of Clinical Oncology meeting, the analyst expects Nektar and partner Bristol-Myers Squibb (BMY) to unveil data from at least 40 advanced melanoma patients "supported by in-depth biomarker characterization to comprehensively ascertain the rationale of combining NKTR-214 with Opdivo." The rationale for combining NKTR-214 with Opdivo is "more robust" than epacadostat plus Keytruda, the analyst contends. Further, he believes data generated by the NKTR-214 plus Opdivo combination is "unambiguous." Chattopadhyay reiterates a Buy rating on Nektar shares with a $125 price target.
04/06/18
MZHO
04/06/18
NO CHANGE
Target $103
MZHO
Buy
Mizuho says failure of Incyte's epacadostat ups chances of Nektar takeover
Mizuho analyst Difei Yang raised her price target on Nektar Therapeutics (NKTR) to $103 from $89 after Incyte (INCY) announced this morning the failure of epacadostat in combination with Merck's (MRK) Keytruda in a phase 3 study in melanoma patients. Recent clinical data presented by Nektar reinforced her view of NKTR-214 as one of the most impressive combo agent for checkpoint inhibitors, said Yang, who believes that the failure of epacadostat raises the possibility of a takeout by Bristol-Myers (BMY) in the coming months. She maintains a Buy rating on Nektar shares, which are down 8.5% to $92.75 in afternoon trading.

TODAY'S FREE FLY STORIES

02:50
10/18/18
10/18
02:50
10/18/18
02:50
General news
FX Update: The Dollar has traded mostly firmer »

FX Update: The Dollar has…

01:45
10/18/18
10/18
01:45
10/18/18
01:45
General news
Asian Market Wrap: »

Asian Market Wrap:…

01:45
10/18/18
10/18
01:45
10/18/18
01:45
General news
Breaking General news story  »

8-Week Bill Settlement to…

23:10
10/17/18
10/17
23:10
10/17/18
23:10
General news
Asia Market Action: equities are mixed »

Asia Market Action:…

PHAS

PhaseBio

$0.00

(0.00%)

21:06
10/17/18
10/17
21:06
10/17/18
21:06
Syndicate
PhaseBio 9.2M share IPO priced at $5.00 »

The deal size was…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Oct

MSC

Studio City

$0.00

(0.00%)

21:00
10/17/18
10/17
21:00
10/17/18
21:00
Syndicate
Studio City 28.75M share IPO priced at $12.50 »

The deal was priced at…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Oct

BHGE

Baker Hughes

$30.75

-0.09 (-0.29%)

, CJ

C&J Energy Services

$20.40

-0.12 (-0.58%)

20:38
10/17/18
10/17
20:38
10/17/18
20:38
Recommendations
Baker Hughes, C&J Energy Services, FTS International, Halliburton, Keane Group, Nabors Industries, Nine Energy Services, Patterson-UTI, ProPetro Holding, Schlumberger, Covia , Helmerich & Payne, U.S. Silica, Weatherford analyst commentary at BofA/Merrill »

BofA/Merrill reinstating…

BHGE

Baker Hughes

$30.75

-0.09 (-0.29%)

CJ

C&J Energy Services

$20.40

-0.12 (-0.58%)

FTSI

FTS International

$12.87

-0.115 (-0.89%)

HAL

Halliburton

$39.56

-0.52 (-1.30%)

FRAC

Keane Group

$12.50

-0.14 (-1.11%)

NBR

Nabors Industries

$6.25

-0.175 (-2.72%)

NINE

Nine Energy Services

$39.10

0.31 (0.80%)

PTEN

Patterson-UTI

$16.58

-0.37 (-2.18%)

PUMP

ProPetro Holding

$18.19

-0.315 (-1.70%)

SLB

Schlumberger

$59.24

-0.43 (-0.72%)

CVIA

Covia

$7.01

-0.57 (-7.52%)

HP

Helmerich & Payne

$68.06

-1.13 (-1.63%)

SLCA

U.S. Silica

$17.69

-1.03 (-5.50%)

WFT

Weatherford

$2.61

-0.03 (-1.14%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Oct

  • 19

    Oct

  • 22

    Oct

  • 23

    Oct

  • 24

    Oct

  • 25

    Oct

  • 29

    Oct

  • 30

    Oct

  • 30

    Oct

  • 01

    Nov

  • 01

    Nov

PM

Philip Morris

$84.62

1.12 (1.34%)

, DHR

Danaher

$104.95

-0.13 (-0.12%)

20:25
10/17/18
10/17
20:25
10/17/18
20:25
Earnings
Notable companies reporting before tomorrow's open »

Notable companies…

PM

Philip Morris

$84.62

1.12 (1.34%)

DHR

Danaher

$104.95

-0.13 (-0.12%)

BK

BNY Mellon

$49.16

-0.17 (-0.34%)

NVS

Novartis

$85.34

-0.41 (-0.48%)

BX

Blackstone

$36.06

-0.02 (-0.06%)

BBT

BB&T

$47.73

0.64 (1.36%)

TRV

Travelers

$126.47

1.75 (1.40%)

PPG

PPG

$98.15

-0.06 (-0.06%)

KEY

KeyCorp

$18.75

0.17 (0.91%)

NUE

Nucor

$59.11

0.17 (0.29%)

TXT

Textron

$64.72

-2.01 (-3.01%)

GPC

Genuine Parts

$95.26

-1.83 (-1.88%)

DOV

Dover

$82.28

-0.95 (-1.14%)

WBC

Wabco

$103.09

-6.91 (-6.28%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Oct

  • 18

    Oct

  • 18

    Oct

  • 18

    Oct

  • 18

    Oct

  • 18

    Oct

  • 18

    Oct

  • 18

    Oct

  • 18

    Oct

  • 18

    Oct

  • 18

    Oct

  • 18

    Oct

  • 19

    Oct

  • 19

    Oct

  • 29

    Oct

  • 30

    Oct

  • 06

    Nov

  • 07

    Nov

  • 16

    Nov

  • 13

    Dec

  • 18

    Oct

AVMXY

Avita Medical

$0.00

(0.00%)

19:55
10/17/18
10/17
19:55
10/17/18
19:55
Hot Stocks
Avita Medical announces first U.S. sales of Recell system »

AVITA Medical announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FRAC

Keane Group

$12.50

-0.14 (-1.11%)

19:33
10/17/18
10/17
19:33
10/17/18
19:33
Initiation
Keane Group initiated at BofA/Merrill »

Keane Group initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Nov

NBR

Nabors Industries

$6.25

-0.175 (-2.72%)

19:28
10/17/18
10/17
19:28
10/17/18
19:28
Initiation
Nabors Industries initiated at BofA/Merrill »

Nabors Industries…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Oct

NINE

Nine Energy Services

$39.10

0.31 (0.80%)

19:19
10/17/18
10/17
19:19
10/17/18
19:19
Initiation
Nine Energy Services initiated at BofA/Merrill »

Nine Energy Services…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Oct

PTEN

Patterson-UTI

$16.58

-0.37 (-2.18%)

19:17
10/17/18
10/17
19:17
10/17/18
19:17
Initiation
Patterson-UTI initiated at BofA/Merrill »

Patterson-UTI initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Oct

GSBC

Great Southern Bancorp

$52.51

0.26 (0.50%)

19:04
10/17/18
10/17
19:04
10/17/18
19:04
Earnings
Great Southern Bancorp reports preliminary Q3 EPS $1.18, consensus $1.06 »

Reports Q3 NI $43.0M vs.…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Oct

  • 24

    Oct

HMNY

Helios and Matheson

$0.02

0.001 (5.18%)

18:59
10/17/18
10/17
18:59
10/17/18
18:59
Periodicals
Breaking Periodicals news story on Helios and Matheson »

Helios & Matheson…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BY

Byline Bancorp

$21.33

0.02 (0.09%)

18:51
10/17/18
10/17
18:51
10/17/18
18:51
Hot Stocks
Byline Bancorp to acquire Oak Park River Forest Bankshares for $42M »

Byline Bancorp and Oak…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Oct

ABB

ABB

$21.37

-0.115 (-0.54%)

18:48
10/17/18
10/17
18:48
10/17/18
18:48
Periodicals
ABB weighs divesting $10B power grid business, Bloomberg reports »

ABB is working with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VEC

Vectrus

$28.98

-0.74 (-2.49%)

18:22
10/17/18
10/17
18:22
10/17/18
18:22
Hot Stocks
Vectrus names Kevin Boyle chief legal officer »

Vectrus announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

S

Sprint

$6.41

-0.005 (-0.08%)

18:21
10/17/18
10/17
18:21
10/17/18
18:21
Hot Stocks
Sprint extends credits to Florida customers impacted by Hurricane Michael »

Sprint said it continues…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Nov

TALO

Talos Energy

$29.85

-1.49 (-4.75%)

18:05
10/17/18
10/17
18:05
10/17/18
18:05
Hot Stocks
Talos Energy reaches pact with Hokchi to cross-assign interests »

Talos Energy Inc.…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Nov

STLD

Steel Dynamics

$40.55

0.29 (0.72%)

18:05
10/17/18
10/17
18:05
10/17/18
18:05
Hot Stocks
Steel Dynamics CEO says 'delivered a tremendous third quarter performance' »

"The team delivered…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Oct

STLD

Steel Dynamics

$40.55

0.29 (0.72%)

18:02
10/17/18
10/17
18:02
10/17/18
18:02
Hot Stocks
Steel Dynamics CEO: We believe steel consumption will continue to be strong »

"We remain confident…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Oct

STLD

Steel Dynamics

$40.55

0.29 (0.72%)

18:01
10/17/18
10/17
18:01
10/17/18
18:01
Earnings
Steel Dynamics reports Q3 adjusted EPS $1.69, consensus $1.64 »

Reports Q3 revenue $3.2B,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Oct

CRTO

Criteo

$23.00

-0.29 (-1.25%)

, RUBI

Rubicon Project

$3.77

-0.06 (-1.57%)

17:44
10/17/18
10/17
17:44
10/17/18
17:44
Periodicals
Advertising technology firm DataXu exploring sale, WSJ says »

DataXu, which offers…

CRTO

Criteo

$23.00

-0.29 (-1.25%)

RUBI

Rubicon Project

$3.77

-0.06 (-1.57%)

FUEL

Rocket Fuel

$0.00

(0.00%)

GOOG

Alphabet

$1,115.99

-4.12 (-0.37%)

FB

Facebook

$159.46

0.65 (0.41%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Oct

  • 25

    Oct

  • 28

    Oct

  • 30

    Oct

  • 07

    Nov

  • 07

    Nov

  • 15

    Nov

  • 16

    Nov

  • 03

    Mar

BTU

Peabody Energy

$36.09

-0.31 (-0.85%)

17:37
10/17/18
10/17
17:37
10/17/18
17:37
Hot Stocks
Peabody Energy increases quarterly dividend nearly 4% to 13c per share »

Peabody Energy announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.